Cabaletta Bio, Inc. (CABA)
2.91
-0.36
(-11.01%)
USD |
NASDAQ |
Sep 09, 16:00
2.96
+0.05
(+1.72%)
After-Hours: 04:43
Cabaletta Bio Debt to Equity Ratio : 0.1221 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1221 |
| March 31, 2026 | 0.256 |
| December 31, 2025 | 0.2418 |
| September 30, 2025 | 0.1848 |
| June 30, 2025 | 0.1395 |
| March 31, 2025 | 0.2369 |
| December 31, 2024 | 0.1024 |
| September 30, 2024 | 0.0874 |
| June 30, 2024 | 0.0371 |
| March 31, 2024 | 0.0368 |
| December 31, 2023 | 0.0212 |
| September 30, 2023 | 0.0265 |
| June 30, 2023 | 0.0241 |
| March 31, 2023 | 0.051 |
| December 31, 2022 | 0.0492 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | -3.757 |
| December 31, 2018 | -4.109 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 256.73M |
| Total Liabilities (Quarterly) | 46.14M |
| Shareholders Equity (Quarterly) | 210.59M |
| Current Ratio | 5.789 |
| Net Debt Paydown Yield | 0.12% |